Antiviral efficacy of pralatrexate against sars-cov-2

Joon Yong Bae, Gee Eun Lee, Heedo Park, Juyoung Cho, Jeonghun Kim, Jungmin Lee, Kisoon Kim, Jin Il Kim, Man Seong Park

Research output: Contribution to journalArticlepeer-review

Abstract

Novel coronavirus (SARS-CoV-2) has caused more than 100 million confirmed cases of human infectious disease (COVID-19) since December 2019 to paralyze our global community. However, only limited access has been allowed to COVID-19 vaccines and antiviral treatment options. Here, we report the efficacy of the anticancer drug pralatrexate against SARS-CoV-2. In Vero and human lung epithelial Calu-3 cells, pralatrexate reduced viral RNA copies of SARS-CoV-2 without detectable cytotoxicity, and viral replication was successfully inhibited in a dose-dependent manner. In a time-to-addition assay, pralatrexate treatment at almost half a day after infection also exhibited inhibitory effects on the replication of SARS-CoV-2 in Calu-3 cells. Taken together, these results suggest the potential of pralatrexate as a drug repurposing COVID-19 remedy.

Original languageEnglish
Pages (from-to)268-272
Number of pages5
JournalBiomolecules and Therapeutics
Volume29
Issue number3
DOIs
Publication statusPublished - 2021

Keywords

  • Antiviral
  • COVID-19
  • Drug repurposing
  • SARS-CoV-2

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery

Fingerprint

Dive into the research topics of 'Antiviral efficacy of pralatrexate against sars-cov-2'. Together they form a unique fingerprint.

Cite this